Fact CheckerSign in

NCT06548789RecruitingPhase 2

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

Source: ClinicalTrials.gov · Last updated 25 Sept 2026

Brief summary (registry, in English)

To Determine the feasibility, compliance and adherence to PreFED intervention in resectable melanoma patients initiating neoadjuvant Ipi/Nivo.

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
35 (estimated)
First submitted
8 Aug 2024
Start date
16 Sept 2024
Primary completion date
1 Sept 2028
Lead sponsor
M.D. Anderson Cancer Center
Diseases
Melanoma
NCT number
NCT06548789

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 35
  • From 16 Sept 2024 to the primary completion date, 1 Sept 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Currently taking steroids \> prednisone 10 mg/day or equivalent
  • Current smoker or heavy drinker (defined as \>14 drinks per week) or current illicit drug use
  • Concurrent malignancy requiring systemic therapy other than hormonal therapy

Other illness

  • History of inflammatory bowel disease, total colectomy, or bariatric surgery
  • Self-reported major dietary restrictions, including but not limited to relevant food allergies, celiac disease, or diets such as vegan, ketogenic, extended fasting
  • Insulin-dependent diabetes or conditions requiring bile-acid sequestrants

Other

  • Uveal melanoma
  • Medical contraindications to the intervention diet as determined by the treating physician
  • Unable or unwilling to undergo study procedures
  • Intravenous (IV) antibiotic \>1 dose in the past month or 1 dose IV/oral antibiotic use in past 2 weeks
  • Regularly taking supplements containing prebiotics, fiber and/or probiotics, and unable/unwilling to discontinue for the purpose of the study
  • Currently pregnant, planning to become pregnant, or lactating
  • Cognitively impaired adults

Who the study is looking for

  • Age ≥ 18 years old.
  • Body mass index (BMI) 18.5-45 kg/m2
  • Able to self-complete study assessments monitoring diet and gastrointestinal symptom burden
  • ECOG performance status of 0 or 1
  • Histologically confirmed resectable stage IIIB-D or oligometastatic Stage IV cutaneous melanoma or locally invasive/advanced mucosal melanoma as determined by multidisciplinary review
  • Planned initiation of standard-of-care neoadjuvant anti-PD1 +/- anti-CTLA4 or anti-LAG3 inhibitors or talimogene laherparepvec (T-VEC)
  • Measurable disease per RECIST 1.1
  • WOCP must have negative UPT within 1 week of beginning dietary intervention.
  • Self-reported willingness to eat the provided foods (with some tailoring to their food preferences)
  • Self-reported willingness to comply with scheduled visits, undergo venipuncture, provide stool samples.
  • Archival tissue specimen or planned to undergo tumor biopsy as part of standard of care treatment.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
MD Anderson Cancer Center
Coordinator of this site? Confirm its status
HoustonUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.